BILL · 2017–18 SESSION
HB 2304: Diversity in clinical trials
Concerning improving diversity in clinical trials.
Summary
- Directs the Washington State Review Board to establish a program to encourage diversity in clinical trials for drugs and medical devices for underrepresented demographic groups.
- Requires state entities that conduct clinical trials of drugs or medical devices to adopt policies for identifying and recruiting members of underrepresented demographic groups to participate in clinical trials.
From the House Bill Analysis 2018 (HB 2304), written by the Legislature's nonpartisan staff. Read the full report ↗
Did not pass Did not pass · died in committee
- IntroducedJan 8, 2018
- Out of committeestopped here
- Passed House
- Passed Senate
- Governor
- Law
- Prime sponsor
- John Lovick (D-44)
- Introduced
- January 8, 2018 in the House
- Last action
- January 8, 2018
- Companion bill
- SB 6506
- Budget
- Has a fiscal note
AN ACT Relating to improving diversity in clinical trials;
Sponsors
Prime sponsor: John Lovick (D-44)
12 co-sponsors (12 Democrats, 0 Republicans)
Votes
No recorded floor votes. This measure never reached a floor vote.
History
- First reading, referred to Health Care & Wellness (Not Officially read and referred until adoption of Introduction report).
- Prefiled for introduction.
HB 2304 in other sessions
Bill numbers restart every two years, so the same number is a different bill in each session.
- HB 2304 (2025–26) Condominium warranties
- HB 2304 (2023–24) UW primate research center
- HB 2304 (2019–20) Shared leave/L&I benefits
- HB 2304 (2015–16) Naturopaths, rx authority
- HB 2304 (2013–14) Marijuana licenses
- HB 2304 (2011–12) Low-level radioactive waste
- HB 2304 (2009–10) Child victims & witnesses
- HB 2304 (2007–08) Cardiac care services